GKOS (Glaukos) Accounts Payable: $19.2 Mil (As of Mar. 2026)


GKOS Glaukos Corp GKOS
79 GF Score
Price $144.42
GF Value $135.47
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Accounts Payable?

Glaukos GKOS +1.30% 79 Accounts Payable is $19.2 Mil as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review.

Glaukos's Accounts Payable for the quarter that ended in Mar. 2026 was $19.2 Mil.

Glaukos's quarterly Accounts Payable increased from Sep. 2025 ($19.9 Mil) to Dec. 2025 ($24.6 Mil) but then declined from Dec. 2025 ($24.6 Mil) to Mar. 2026 ($19.2 Mil).

Glaukos's annual Accounts Payable declined from Dec. 2023 ($13.4 Mil) to Dec. 2024 ($13.0 Mil) but then increased from Dec. 2024 ($13.0 Mil) to Dec. 2025 ($24.6 Mil).

Glaukos Accounts Payable Historical Data

* Premium members only.

The historical data trend for Glaukos's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Accounts Payable Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 14.40 13.44 13.03 24.62

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.83 13.68 19.88 24.62 19.15
GKOS
79GF Score
Glaukos Corp GKOS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $19.2 Mil mean?
Glaukos (GKOS) has a Accounts Payable of $19.2 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Glaukos and its competitors.
Is Glaukos' Accounts Payable too high?
Glaukos' current Accounts Payable is $19.2 Mil. Overall, Glaukos has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Accounts Payable compare to BIO and BRKR?
Glaukos' Accounts Payable of $19.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Glaukos and its competitors. Glaukos's current Accounts Payable is $19.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $144.42 — trading 6.6% above its estimated fair value. The current Accounts Payable is $19.2 Mil. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Glaukos (GKOS), the current Accounts Payable is $19.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $144.42 is trading 6.6% above its estimated GF Value™ of $135.47. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Accounts Payable: $19.2 Mil
  • GF Value™: $135.47 vs. price of $144.42 (6.6% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score

Get the complete analysis for GKOS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$144.42
Price
$135.47
GF Value